The Genome Editing Market size in the Asia Pacific was worth USD 0.71 billion in 2020 and estimated to be growing at a CAGR of 15.66% to reach USD 1.47 billion by 2025 during the forecast period.
Genome editing is a branch of genetic engineering in which DNA is inserted, deleted, or replaced in the genome of a living organism with the aid of engineered nucleases, which are otherwise known as molecular scissors. They work by creating site-specific double-strand breaks at the desired locations in the genome.
Genome Editing is used for research to understand the biology and inner workings of cells, to treat diseases such as modifying human blood cells to treat conditions such as leukemia and AIDS. Other applications include in the field of biotechnology, where it is used to modify crops to increase their yield and their resistance to diseases and drought. Another new application is genetically modifying cattle to develop them without horns.
The significant factors affecting the Asia-Pacific Genome Editing market include technological advancements concerning the development of novel vectors used in genome editing and rising competition among operating companies to get a larger market share. Another driver for the market is the emerging interest in genome editing by pharmaceutical and biotechnological companies.
Despite this, the toxicity due to off-target effects of nucleases is still a safety concern for the market. Additionally, the IP disputes related to the use of CRISPR technology amongst the industry players are also expected to act as restraints for the market.
This research report has been segmented and sub-segmented into the following categories:
Regionally, the Chinese genome editing market is projected to have fast growth in this region over the review period, followed by Japan, India, and other countries. The growth of China is attributed due to factors such as advanced technologies in developing new novel drugs for genome editing, growing elder people population, and changing lifestyle, which may lead to chronic disorders of this APAC region is likely to accelerate the market growth. In April 2016, Japan invested nearly USD 76million for the next five years for the creation of Japanese owned genome editing technologies over the analysis period.
Few of the top companies leading the Asia Pacific Genome Editing Market profiled in the report are Thermo Fisher Scientific, Merck KGAA, Horizon Discovery Group Plc, Genscript Biotech Corporation, Sangamo Biosciences, Integrated DNA Technologies, Lonza Group Ltd, New England Biolabs, Origene Technologies, and Transposagen Biopharmaceuticals.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Application
5.1.1 Introduction
5.1.2 Cell Line Engineering
5.1.3 Animal Genetic Engineering
5.1.4 Plant Genetic Engineering
5.1.5 Y-o-Y Growth Analysis, By Application
5.1.6 Market Attractiveness Analysis, By Application
5.1.7 Market Share Analysis, By Application
5.2 Technology
5.3.1 Introduction
5.3.2 CRISPR
5.3.3 TALEN
5.3.4 ZFN
5.3.5 Antisense
5.3.6 Other Technologies
5.3.7 Y-o-Y Growth Analysis, By Technology
5.3.8 Market Attractiveness Analysis, By Technology
5.3.9 Market Share Analysis, By Technology
5.3 End User
5.2.1 Introduction
5.2.2 Biotechnological & Pharmaceutical Companies
5.2.3 Academic and Government Research Institutes
5.2.4 Contract Research Organizations
5.2.5 Y-o-Y Growth Analysis, By End User
5.2.6 Market Attractiveness Analysis, By End User
5.2.7 Market Share Analysis, By End User
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Application
6.1.3.3 By Technology
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Application
6.1.4.3 By Technology
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Application
6.1.5.3 By Technology
6.1.5.4 By End User
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five Analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Thermo Fisher Scientific
8.1.1 Overview
8.1.2 Application Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Merck KGAA
8.3 Horizon Discovery Group Plc
8.4 Genscript Biotech Corporation
8.5 Sangamo Biosciences
8.6 Integrated DNA Technologies
8.7 Lonza Group Ltd
8.8 New England Biolabs
8.9 Origene Technologies
8.10 Transposagen Biopharmaceuticals
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
Appendix
Related Reports
